These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 32862455)

  • 21. LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome.
    Thurner L; Fadle N; Bittenbring JT; Regitz E; Schuck R; Cetin O; Stuhr A; Rixecker T; Murawski N; Poeschel V; Kaddu-Mulindwa D; Preuss KD; Stilgenbauer S; Hermine O; Kluin-Nelemans HC; Hartmann S; Dreyling M; Pott C; Bewarder M; Hoster E
    Blood; 2021 Jun; 137(23):3251-3258. PubMed ID: 33513604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
    Klener P; Fronkova E; Kalinova M; Belada D; Forsterova K; Pytlik R; Blahovcova P; Simkovic M; Salek D; Mocikova H; Prochazka V; Janikova A; Vaskova M; Mejstrikova E; Kodet R; Trka J; Trneny M
    Hematol Oncol; 2018 Dec; 36(5):773-778. PubMed ID: 30129045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan.
    Chihara D; Asano N; Ohmachi K; Kinoshita T; Okamoto M; Maeda Y; Mizuno I; Matsue K; Uchida T; Nagai H; Nishikori M; Nakamura S; Ogura M; Suzuki R
    Br J Haematol; 2015 Sep; 170(5):657-68. PubMed ID: 25953436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Unusual sites of involvement in non-Hodgkin's lymphoma: Case 3. Intussusception as a rare complication of mantle-cell lymphoma.
    Sucker C; Klima KM; Doelken G; Heidecke CD; Lorenz G; Stockschlaeder M
    J Clin Oncol; 2002 Nov; 20(21):4397-8. PubMed ID: 12409341
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report.
    Jo JC; Kim SJ; Lee HS; Eom HS; Lee SI; Park Y; Lee JO; Lee Y; Yhim HY; Yang DH; Byun JM; Kang HJ; Kim HJ; Shin HJ; Yoo KH; Suh C;
    Ann Hematol; 2020 Feb; 99(2):223-228. PubMed ID: 31853704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients.
    Voropaeva EN; Voevoda MI; Pospelova TI; Maksimov VN
    Br J Haematol; 2015 Apr; 169(1):32-5. PubMed ID: 25430047
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mantle cell lymphoma as a rare cause of intussusception: a report of 2 cases.
    Grin A; Chetty R; Bailey D
    Ann Diagn Pathol; 2009 Dec; 13(6):398-401. PubMed ID: 19917477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
    Martin P; Chadburn A; Christos P; Furman R; Ruan J; Joyce MA; Fusco E; Glynn P; Elstrom R; Niesvizky R; Feldman EJ; Shore TB; Schuster MW; Ely S; Knowles DM; Chen-Kiang S; Coleman M; Leonard JP
    Ann Oncol; 2008 Jul; 19(7):1327-1330. PubMed ID: 18349031
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Optimal frontline management of mantle cell lymphoma: can we agree?
    Tang C; Kuruvilla J
    Expert Rev Hematol; 2018 Dec; 11(12):911-914. PubMed ID: 30336708
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T
    Tessoulin B; Bouabdallah K; Burroni B; Lamy T; Gressin R; Cartron G; Thieblemont C; Sarkozy C; Haioun C; Casasnovas O; Joubert C; Gyan E; Hermine O; Le Gouill S
    Ann Hematol; 2020 Aug; 99(8):1771-1778. PubMed ID: 32601796
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma.
    Jacobsen E; Freedman A
    Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
    Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
    Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.
    Karmali R; Larson ML; Wooldridge JE; Gregory SA; O'Brien T; Shammo JM; Bueschel K; Venugopal P
    Leuk Lymphoma; 2011 Nov; 52(11):2097-104. PubMed ID: 21702643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP.
    Liu Y; Wang X; Ding N; Mi L; Ping L; Jin X; Li J; Xie Y; Ying Z; Liu W; Zhang C; Deng L; Song Y; Zhu J
    BMC Cancer; 2017 Nov; 17(1):743. PubMed ID: 29126407
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
    J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
    Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
    Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.
    Campiotti L; Suter MB; De Palma D; Proserpio I; Uccella S; Squizzato A
    Hematol Oncol; 2019 Aug; 37(3):308-309. PubMed ID: 30933368
    [No Abstract]   [Full Text] [Related]  

  • 38. Mantle cell lymphoma: a Turkish Multi-Center Study.
    Okay M; Meletli O; Kelkitli E; Malkan UY; Turgut M; Buyukasik Y; Tekin F; Demiroglu H; Goker H
    J BUON; 2019; 24(5):2084-2089. PubMed ID: 31786879
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
    Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous stem cell transplantation in patients with mantle cell lymphoma.
    Oinonen R; Jantunen E; Itälä M; Lehtinen T; Kuittinen O; Franssila K; Wiklund T; Elonen E
    Leuk Lymphoma; 2002 Jun; 43(6):1229-37. PubMed ID: 12152990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.